About Us

The Children’s Oncology Group (COG) is the most experienced organization in the world in clinical development of new therapeutics for children and adolescents with cancer.

The Children’s Oncology Group Phase 1 & Pilot Consortium is a limited institution consortium, comprised of 21 premier pediatric oncology programs in the country that were selected through a peer review process. Formed in 2002, the primary goals of the consortium are to identify and develop effective new agents for children and adolescents with cancer through rational and efficient clinical and laboratory research. The consortium serves as a national and international model for new drug development in pediatric oncology.

The consortium successfully leverages the database infrastructure and resources of the parent Children’s Oncology Group (COG) while maintaining its own administrative and operational infrastructure to ensure rapid development, implementation and reporting of specialized and complex early phase clinical trials. The consortium has expert resources for the conduct of translational biology, pharmacokinetic, and pharmacogenetics studies, and has developed a state-of-the art infrastructure to facilitate image transfer of specialized correlative imaging studies for central review and analyses.

DVL Chair
Susan M. Blaney, MD
Texas Children's Cancer Center / Baylor College of Medicine
6621 Fannin Street, CC 1410.00
Houston, TX 77030-2399
Tel: (832) 822-1482
Fax: (832) 825-4299
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

DVL Vice-Chair
Dr. Brenda J. Weigel, MD
University of Minnesota Medical Center-Fairview
Department of Pediatrics, Hem/Onc/BMT
420 Delaware Street, SE
MMC 366
Minneapolis, MN 55455
Tel: 612 626-5501
Fax: 612 624-3913
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

COG Operations Center
440 E. Huntington Drive, 4th Floor
Arcadia, CA 91006-3776
Tel: (626) 447-0064
Fax: (626) 445-4334


 

Our Mission

The primary mission of the COG Phase I & Pilot Consortium is to identify and develop effective new agents for children and adolescents with cancer through rational and efficient clinical and laboratory research.

 

Research Funding

COG Phase 1 Consortium grant, supporting 21 premier COG institutions charged with early phase clinical trials, is primarily funded by the National Cancer Institute and also receives additional funding from other granting agencies and from philanthropic sources (http://cog-foundation.org ).